- Sarepta Therapeutics (SRPT, Financial) is expected to release Q1 earnings with an anticipated EPS of -$0.65.
- Revenue is projected to grow by 65.4%, reaching $684.12 million.
- Analyst price targets suggest a significant potential upside, with an average target price of $148.04.
Sarepta Therapeutics: Anticipating the Earnings Release
Sarepta Therapeutics (SRPT), a renowned name in the biotech sector, is gearing up to announce its first-quarter earnings after the market closes on May 6th. Investors are bracing for an expected earnings per share (EPS) of -$0.65, signaling a notable decline. However, revenue is projected to soar by 65.4% to a substantial $684.12 million. This comes amidst a backdrop of the company frequently surpassing revenue expectations, even as EPS and revenue projections have seen diverse adjustments of late.
Wall Street Analysts' Projections
The outlook from Wall Street analysts remains optimistic. According to the one-year price targets set by 23 experts, Sarepta Therapeutics Inc (SRPT, Financial) has an average target price of $148.04. Projections vary from a high of $209.00 to a low of $70.00. With these estimates, the average target suggests a potential upside of 132.55% from the current trading price of $63.66. For more comprehensive forecast data, visit the Sarepta Therapeutics Inc (SRPT) Forecast page.
Brokerage Recommendations and GF Value Assessment
Furthermore, consensus from 25 brokerage firms classifies Sarepta Therapeutics Inc's (SRPT, Financial) status as "Outperform," with an average recommendation score of 1.8. The rating scale, ranging from 1 (Strong Buy) to 5 (Sell), positions Sarepta favorably among industry players.
Delving into the GF Value provided by GuruFocus, Sarepta Therapeutics Inc (SRPT, Financial) carries an estimated one-year value of $218.09. This projection underscores a potential upside of 242.59% from its current price of $63.66. The GF Value is GuruFocus's estimate of the fair trading value of the stock, derived from historical multiples and anticipated business performance. For a deeper dive, explore the Sarepta Therapeutics Inc (SRPT) Summary page.
